Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UMC Cancer Center / UMC Health System — Lubbock, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- Memorial Hermann Texas Medical Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- MD Anderson League City — League City, Texas
- MD Anderson in Sugar Land — Sugar Land, Texas
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Texas: - The University of Texas — Houston, Texas
- University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of f…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03741673
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Community Clinical Trials — Kingwood, Texas
- Tranquil Clinical Research — Webster, Texas
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Texas: - UT Southwestern — Dallas, Texas
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed …
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT02704858
Sites in Texas: - Baylor Scott & White Health — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Texas: - Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Texas: - UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose ch…
Sponsor: Medical University of Vienna
NCT ID: NCT01356290
Sites in Texas: - Dell Children's Medical Group SFC-HEM/ONC — Austin, Texas
Phase 2 Recruiting Academic/Other
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein,…
Sponsor: The University of Texas Health Science Center at San Antonio
NCT ID: NCT04559230
Sites in Texas: - Texas Oncology Austin — Austin, Texas
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center — San Antonio, Texas